Detection of renal failure by cardiac implantable medical device

• US 7,529,580 B2
• Filed: 08/11/2005
• Issued: 05/05/2009
• Est. Priority Date: 08/11/2005
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories)
• Inventors: Gill, Jong, Bornzin, Gene A.
• Primary Examiner(s): Layno; Carl H
• Assistant Examiner(s): MALAMUD, DEBORAH LESLIE
• Application Number:
  US11/202,534
• Publication Number:
  US 20070038138A1
• Time in Patent Office: 1,363 Days
• Field of Search: 600/509, 600/513, 600/13, 600/609, 607/25
• US Class Current: 600/513
• CPC Class Codes: A61B 5/201 Assessing renal or kidney functions
• CPC Class Codes: A61B 5/349 Detecting specific parameters of the electrocardiograph cycle
• CPC Class Codes: A61N 1/3702 Physiological parameters A61N1/365 takes precedence; evoked response A61N1/371

Abstract

Morphological features within electrical cardiac signals are tracked and feature changes are monitored to detect renal failure. The morphological feature may be an interval between corresponding polarization events such as the interval between QRS-complexes and peaks of corresponding T-waves (QTmax interval); the interval between QRS-complexes and ends of corresponding T-waves (QTend interval); or the interval between P-waves and corresponding QRS-complexes (PR interval). The feature may also be the elevation of a cardiac signal segment between corresponding polarization events, such as QRS-complexes and corresponding T-waves (ST segment); a duration of a polarization event, such as a QRS-complex (QRS width); or an amplitude of a polarization event, such as a T-wave (T-wave amplitude). The change in the feature may comprise a decrease in QTmax intervals, a decrease in QTend intervals, a deviation in ST segment elevation, an increase in QRS width, an increase in PR interval or a deviation in T-wave amplitude.

Claims

1. An implantable medical system for detecting renal failure comprising:

at least one lead comprising an electrode configured for placement within a patient in electrical contact with the patient'"'"'s heart and operative to sense intracardiac electrograms;

an implantable medical device adapted to be connected to the at least one lead and comprising;

a tracking unit that tracks two different intervals between QRS complexes and corresponding T waves for each of at least two different PQRST complexes within an intracardiac electrogram sensed by the at least one lead; and

a renal failure detection unit that detects renal failure if each of the two different intervals decrease by a respective amount, wherein the renal failure detection unit calculates a renal failure burden representative of a proportion of time renal failure is detected.

2. The system of claim 1 wherein one of the two different intervals is an interval between QRS-complexes and ends of corresponding T-waves (QTend intervals) and its respective amount is a percentage of a baseline QTend interval.

3. The system of claim 1 wherein one of the two different intervals is an interval between QRS-complexes and peaks of corresponding T-waves (QTmax intervals) and its respective amount is a percentage of a baseline QTmax interval.

4. The system of claim 1 further comprising a pulse generator that delivers a pacing pulse to the at least one lead to induce an evoked response element of the PQRST complexes.

5. An implantable medical system for detecting renal failure comprising:

at least one lead comprising an electrode configured for placement within a patient in electrical contact with the patient'"'"'s heart and operative to sense intracardiac electrograms;

an implantable medical device adapted to be connected to the at least one lead and comprising;

a tracking unit that tracks two different intervals between QRS complexes and corresponding T waves for each of at least two different PQRST complexes within an intracardiac electrogram sensed by the at least one lead, wherein the tracking unit also tracks at least one other morphological feature, distinct from the two different intervals, for each of the at least two different PQRST complexes within an intracardiac electrogram sensed by the lead; and

a renal failure detection unit that detects renal failure if each of the two different intervals decrease by a respective amount and the at least one other morphological feature changes.

6. The system of claim 5 wherein the at least one other morphological feature comprises the elevation of a segment of a cardiac signal between QRS-complexes and corresponding T-waves (ST segment) and a change comprises an increase or decrease in the ST segment with respect to a baseline elevation.

7. The system of claim 5 wherein the at least one other morphological feature comprises the peak amplitude of a polarization event (T-wave amplitude) and a change comprises an increase or a decrease in the T-wave amplitude with respect to a baseline amplitude.

8. The system of claim 5 wherein the at least one other morphological feature comprises the interval between P-waves and corresponding QRS-complexes (PR interval) and a change comprises an increase in the PR interval with respect to a baseline interval.

9. The system of claim 5 wherein the at least one other morphological feature comprises the width of QRS-complexes and a change comprises an increase in the QRS width with respect to a baseline width.